CoChat

PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma

Open access
Budczies, Jan, Mechtersheimer, Gunhild, Denkert, Carsten, Klauschen, Frederick, Mughal, Sadaf S., Chudasama, Priya, Bockmayr, Michael, Jöhrens, Korinna, Endris, Volker, Lier, Amelie, Lasitschka, Felix, Penzel, Roland, Dietel, Manfred, Brors, Benedikt, Gröschel, Stefan, Glimm, Hanno, Schirmacher, Peter, Renner, Marcus, Fröhling, Stefan, Stenzinger, Albrecht · 2017 · OncoImmunology
Cited by 55

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Soft-tissue sarcomas (STS) are rare malignancies that account for 1% of adult cancers and comprise more than 50 entities. Current therapeutic options for advanced-stage STS are limited. Immune checkpoint inhibitors targeting the PD-1/PD-L1 signaling axis are being explored as new treatment modality in STS; however, the determinants of response to these agents are largely unknown. Using the sarcoma data set of The Cancer Genome Altas (TCGA) and an independent cohort of untreated high-grade STS, we analyzed DNA copy number status and mRNA expression of PD-L1 in a total of 335 STS cases. Copy number gains (CNG) were detected in 54 TCGA cases (21.1%), of which 21 (8.2%) harbored focal PD-L1 CNG and that were most prevalent in myxofibrosarcoma (35%) and undifferentiated pleomorphic sarcoma (34%). In the untreated high-grade STS cohort, we detected CNG in six cases (7.6%). Analysis of co-amplified genes identified a 5.6-Mb core region comprising 27 genes, including JAK2. Patients with PD-L1 CNG had higher PD-L1 expression compared with STS without CNG (fold change, 1.8; p = 0.02), an effect that was most pronounced in the setting of focal PD-L1 CNG (fold change, 3.0; p = 0.0027). STS with PD-L1 CNG showed a significantly higher mutational load compared with tumors with a diploid PD-L1 locus (median number of mutated genes; 58 vs. 40; p = 3.6E-06), and PD-L1 CNG were associated with inferior survival (HR = 1.82; p = 0.025). In contrast, T-cell infiltrates quantified by mRNA expression of CD3Z were associated with improved survival (HR = 0.88; p = 0.024) and consequently influenced the prognostic power of PD-L1 CNG, with low CD3Z levels conferring poor survival in cases with PD-L1 CNG (HR = 1.8; p = 0.049). These data demonstrate that PD-L1 GNG and elevated expression of PD-L1 occur in a substantial proportion of STS, have prognostic impact that is modulated by T-cell infiltrates, and thus warrant investigation as response predictors for immune checkpoint inhibition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2017.1279777

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 55

Metadata

Authors
Budczies, J., Mechtersheimer, G., Denkert, C., Klauschen, F., Mughal, S. S., Chudasama, P., Bockmayr, M., Jöhrens, K., Endris, V., Lier, A., Lasitschka, F., Penzel, R., Dietel, M., Brors, B., Gröschel, S., Glimm, H., Schirmacher, P., Renner, M., Fröhling, S., & Stenzinger, A.
Venue
OncoImmunology
Published
2017-01-27
Volume
6
Issue
3
Pages
e1279777
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W2580171030
Cited by
55
References
6
FWCI
5.87
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. https://app.cochat.ai/papers/10.1080/2162402x.2017.1279777
The paper
Budczies, J., Mechtersheimer, G., Denkert, C., Klauschen, F., Mughal, S. S., Chudasama, P., Bockmayr, M., Jöhrens, K., Endris, V., Lier, A., Lasitschka, F., Penzel, R., Dietel, M., Brors, B., Gröschel, S., Glimm, H., Schirmacher, P., Renner, M., Fröhling, S., & Stenzinger, A. (2017). PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. OncoImmunology. https://doi.org/10.1080/2162402x.2017.1279777

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.